Response rates after induction*
| . | VRD . | VTD . | ||
|---|---|---|---|---|
| GEM2012 . | GEM2005† . | |||
| . | All patients, n (%) . | High-risk cytogenetics, n (%) . | All patients, n (%) . | High-risk cytogenetics, n (%) . |
| (N = 458) . | (n = 92) . | (N = 130) . | (n = 23) . | |
| PR or better | 382 (83.4) | 75 (81.5) | 110 (84.6) | 18 (78.3) |
| CR | 153 (33.4) | 32 (34.8) | 46 (35.4) | 8 (34.8) |
| VGPR | 152 (33.2) | 33 (35.9) | 32 (24.6) | 5 (21.7) |
| PR | 77 (16.8) | 10 (10.9) | 32 (24.6) | 5 (21.7) |
| VGPR or better | 305 (66.6) | 65 (70.7) | 78 (60.0) | 13 (56.5) |
| Stable disease | 20 (4.4) | 0 | 7 (5.4) | 2 (8.7) |
| Progressive disease | 31 (6.8) | 14 (15.2) | 9 (6.9) | 1 (4.3) |
| Not evaluable | 25 (5.5) | 3 (3.3) | ||
| . | VRD . | VTD . | ||
|---|---|---|---|---|
| GEM2012 . | GEM2005† . | |||
| . | All patients, n (%) . | High-risk cytogenetics, n (%) . | All patients, n (%) . | High-risk cytogenetics, n (%) . |
| (N = 458) . | (n = 92) . | (N = 130) . | (n = 23) . | |
| PR or better | 382 (83.4) | 75 (81.5) | 110 (84.6) | 18 (78.3) |
| CR | 153 (33.4) | 32 (34.8) | 46 (35.4) | 8 (34.8) |
| VGPR | 152 (33.2) | 33 (35.9) | 32 (24.6) | 5 (21.7) |
| PR | 77 (16.8) | 10 (10.9) | 32 (24.6) | 5 (21.7) |
| VGPR or better | 305 (66.6) | 65 (70.7) | 78 (60.0) | 13 (56.5) |
| Stable disease | 20 (4.4) | 0 | 7 (5.4) | 2 (8.7) |
| Progressive disease | 31 (6.8) | 14 (15.2) | 9 (6.9) | 1 (4.3) |
| Not evaluable | 25 (5.5) | 3 (3.3) | ||
PR, partial response.
Efficacy data for GEM2012 was adjudicated by an independent response adjudication committee and IMWG criteria. The data for GEM2005 was based on investigator assessment with central review and European Society for Blood and Marrow Transplantation criteria with Uniform Response Criteria for VGPR categorization.
Data from Rosiñol at al.12